Alkermes plc (NASDAQ:ALKS) Receives $44.07 Average PT from Analysts

Alkermes plc (NASDAQ:ALKS) has earned an average rating of “Moderate Buy” from the eighteen research firms that are covering the stock, MarketBeat.com reports. Five investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $44.0667.

ALKS has been the topic of a number of analyst reports. Royal Bank Of Canada cut their target price on Alkermes from $47.00 to $45.00 and set an “outperform” rating on the stock in a research note on Thursday, February 26th. Wolfe Research assumed coverage on Alkermes in a research report on Monday, February 23rd. They issued an “outperform” rating and a $45.00 price objective on the stock. Deutsche Bank Aktiengesellschaft reduced their target price on Alkermes from $55.00 to $45.00 and set a “buy” rating on the stock in a research note on Thursday, November 13th. Bank of America boosted their target price on shares of Alkermes from $33.00 to $34.00 and gave the company a “neutral” rating in a research note on Friday, February 20th. Finally, Wells Fargo & Company upped their price target on shares of Alkermes from $37.00 to $43.00 and gave the stock an “overweight” rating in a report on Thursday, February 26th.

Alkermes Trading Down 2.5%

ALKS stock opened at $27.74 on Friday. Alkermes has a 12 month low of $25.17 and a 12 month high of $36.32. The company has a 50-day moving average price of $31.60 and a 200 day moving average price of $30.23. The stock has a market cap of $4.62 billion, a PE ratio of 19.40, a P/E/G ratio of 7.10 and a beta of 0.53.

Alkermes (NASDAQ:ALKS) last posted its quarterly earnings data on Wednesday, February 25th. The company reported $0.29 earnings per share for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.14). The firm had revenue of $384.55 million during the quarter, compared to analysts’ expectations of $380.44 million. Alkermes had a return on equity of 14.91% and a net margin of 16.37%.The business’s revenue for the quarter was down 10.6% compared to the same quarter last year. During the same period last year, the company earned $1.05 earnings per share. Alkermes has set its FY 2026 guidance at -0.798–0.680 EPS. Sell-side analysts forecast that Alkermes will post 1.31 EPS for the current year.

Insider Activity at Alkermes

In related news, EVP Craig C. Hopkinson sold 9,000 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $29.72, for a total value of $267,480.00. Following the completion of the sale, the executive vice president owned 89,389 shares in the company, valued at approximately $2,656,641.08. The trade was a 9.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Shane Cooke sold 61,200 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $34.57, for a total value of $2,115,684.00. Following the completion of the transaction, the director directly owned 103,744 shares in the company, valued at approximately $3,586,430.08. This trade represents a 37.10% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 157,434 shares of company stock valued at $5,305,794 in the last quarter. Corporate insiders own 4.40% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Baker BROS. Advisors LP lifted its holdings in shares of Alkermes by 23.7% in the 4th quarter. Baker BROS. Advisors LP now owns 10,012,267 shares of the company’s stock worth $280,143,000 after buying an additional 1,920,916 shares during the period. State Street Corp raised its holdings in shares of Alkermes by 10.9% in the fourth quarter. State Street Corp now owns 9,472,858 shares of the company’s stock valued at $265,051,000 after acquiring an additional 932,507 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Alkermes by 6.0% in the fourth quarter. Renaissance Technologies LLC now owns 6,668,028 shares of the company’s stock worth $186,571,000 after acquiring an additional 375,500 shares during the period. JPMorgan Chase & Co. lifted its stake in Alkermes by 32.0% in the fourth quarter. JPMorgan Chase & Co. now owns 5,184,547 shares of the company’s stock worth $145,064,000 after acquiring an additional 1,256,377 shares during the period. Finally, Dimensional Fund Advisors LP grew its holdings in Alkermes by 19.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 4,412,783 shares of the company’s stock worth $123,467,000 after acquiring an additional 714,787 shares in the last quarter. 95.21% of the stock is currently owned by hedge funds and other institutional investors.

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.